The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. Gavin Newsom Halts Ronald Reagan's ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...